Clinical trial · Observational
Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
A Single-center, Non-interventionary Clinical Study Evaluating the Efficacy and Safety of Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
NCT06170216CI-TRIAL-00125637completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunochemotherapies | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- small B-cell non-Hodgkin lymphoma
- description
- Different immunochemotherapies in small B-cell non-Hodgkin lymphoma
- interventionNames
- Drug: immunochemotherapies
Primary outcomes (1)
- measure
- ORR
- timeFrame
- up to 6 months
- description
- the ratio of numbers of patients with complete response and partial response to all the participants receiving treatment
Secondary outcomes (4)
- measure
- 2-year progression-free survival (PFS)
- timeFrame
- From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old * Initial or first recurrent iNHL confirmed by histopathology, including FL (1-3a), MZL, MCL; * Sign an informed consent form; * Researchers evaluate patients who can benefit from receiving immunochemotherapy. Exclusion Criteria: * There are contraindications to any medication in the treatment plan; * Pregnant or lactating women or male and female participants of childbearing age did not take contraceptive measures during the trial period and within 30 days after the last medication; * Researchers believe that patients who are not suitable for enrollment.
References
Publications (0)
Data not yet available
No reference posted for this study.